Story

C4 Therapeutics Stock Gains on Q2 Earnings Beat Despite Revenue Miss

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20261 min read
C4 Therapeutics Stock Gains on Q2 Earnings Beat Despite Revenue Miss
Text size
Background

C4 Therapeutics (ticker: CCCC) shares rose in morning trading after the clinical-stage biopharmaceutical company reported second-quarter financial results that featured a narrower-than-expected loss, even as revenue fell short of analyst forecasts. Management's reaffirmation of its clinical trial timeline provided an additional tailwind for the stock.

Mixed Quarterly Results

The company posted a net loss of $0.18 per share for the second quarter of 2026, outperforming the consensus analyst estimate of a $0.21 loss per share, according to its earnings release. This positive earnings surprise was the primary driver for the stock's move higher.

However, total revenue for the period was $6.64 million, missing the consensus forecast of $8.2 million. C4 Therapeutics noted that revenue was partially affected by the winding down of certain research activities under its collaborations with Merck and Merck KGaA. In response to the report, the stock gained 3.8% in morning trading, reaching a session high of $3.90.

Pipeline Outlook Provides Support

Investors also focused on the company's clinical development pipeline. CEO Andrew Hirsch confirmed that key trials for its lead candidate, cemsidomide, remain on schedule.

Sample IUX Markets – In-articleAd

Key upcoming milestones include:

  • The ongoing Phase 2 MOMENTUM trial.
  • A Phase 1b combination study with elranatamab.

Both studies are on track to deliver clinical data readouts in 2027, providing investors with clear forward-looking catalysts to monitor.

Market Context

The advance in C4 Therapeutics shares was a company-specific reaction, standing out in a largely flat market. The S&P 500 was little changed and the NASDAQ traded slightly lower, indicating no broad market or sector-wide momentum was lifting the stock. The source material also noted no major news from peer companies in the targeted protein degradation space that would have influenced C4's performance.

Read next

More on Stocks
Back to latest news

LATEST